Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RIPRETINIB vs RISDIPLAM: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RIPRETINIB vs RISDIPLAM: Safety Overview

Metric RIPRETINIB RISDIPLAM
Total FAERS Reports 4,432 3,619
Deaths Reported 465 336
Death Rate 10.5% 9.3%
Hospitalizations 948 719
Average Patient Age 66.8 yrs 21.8 yrs
% Female Patients 45.3% 55.2%
FDA Approval Date May 15, 2020 Aug 7, 2020
Manufacturer Deciphera Pharmaceuticals, LLC Genentech, Inc.
Route ORAL ORAL
Marketing Status Prescription Prescription